临床验证临床前磁共振成像预后生物标志物用于头颈癌放疗结局
本研究基于31例局部晚期头颈癌患者放化疗前的扩散加权磁共振成像数据,重新训练并验证了先前在临床前发现的基于表观扩散系数(ADC)的预后影像生物标志物模型。最佳模型定义为800<ADC<1100·10⁻⁶mm²/s,与治疗结局显著相关(p=0.003),高危亚体积(HRS)最佳截断值为5.8 cm³,具有高度显著的预后分层能力(p<0.001,bootstrap AUC≥0.84),而ADCmean无显著分层能力(p=0.361)。
要点
- 基于ADC值800<ADC<1100·10⁻⁶mm²/s定义的高危亚体积与头颈癌放化疗后3年结局显著相关(p=0.003)。
- 高危亚体积最佳截断值为5.8 cm³,预后分层能力与大体肿瘤体积相似(bootstrap AUC≥0.84 vs ≥0.79),优于ADCmean(AUC=0.53)。
- 该临床前预后模型在头颈癌患者中成功重新训练并验证,尚需充分外部验证后方可能用于反应适应性MRI引导放疗。
核心结论
- 基于ADC值定义高危亚体积的临床前预后模型在头颈癌放化疗患者中成功重新训练并验证。
- 作者认为,经过充分外部验证后,这种基于ADC值区间的功能性高危亚体积未来可能允许在线和离线方式实施反应适应性MRI引导放疗。
研究设计与样本
- 31例局部晚期头颈癌患者,在放化疗(35次×2 Gy)前接受3 T MRI的T2加权和扩散加权成像。
- 基于T2加权和b500图像勾画大体肿瘤体积,在低ADC直方图侧翼采用双侧阈值测试不同ADC值区间以确定高危亚体积,并与3年治疗结局相关。
- 最佳模型用于拟合逻辑回归模型,采用bootstrap、受试者工作特征(ROC)分析、Kaplan-Meier法和Cox方法进行内部验证,并与大体肿瘤体积、ADCmean和临床因素比较。
主要发现
- 最佳模型定义为800<ADC<1100·10⁻⁶mm²/s,与治疗结局显著相关(p=0.003)。
- 根据ROC分析,高危亚体积最佳截断值为5.8 cm³。
- 该高危亚体积显示高度显著的分层能力(p<0.001,bootstrap AUC≥0.84),与大体肿瘤体积相似(p<0.001,AUC≥0.79)。
- ADCmean无显著分层能力(p=0.361,AUC=0.53)。
关键数值与推荐
- 最佳模型ADC值区间为800<ADC<1100·10⁻⁶mm²/s。
- 高危亚体积最佳截断值为5.8 cm³(依据ROC分析)。
- 高危亚体积分层能力:p<0.001,bootstrap AUC≥0.84;大体肿瘤体积:p<0.001,AUC≥0.79;ADCmean:p=0.361,AUC=0.53。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To retrain a model based on a previously identified prognostic imaging biomarker using apparent diffusion coefficient (ADC) values from diffusion-weighted magnetic resonance imaging (DW-MRI) in a preclinical setting and validate the model using clinical DW-MRI data of patients with locally advanced head-and-neck cancer (HNC) acquired before radiochemotherapy. MATERIAL AND METHODS: A total of 31 HNC patients underwent T2-weighted and DW-MRI using 3 T MRI before radiochemotherapy (35 x 2 Gy). Gross tumor volumes (GTV) were delineated based on T2-weighted and b500 images. A preclinical model previously revealed that the size of high-risk subvolumes (HRS) defined by a band of ADC-values was correlated to radiation resistance. To validate this model, different bands of ADC-values were tested using two-sided thresholds on the low-ADC histogram flank to determine HRSs inside the GTV and correlated to treatment outcome after three years. The best model was used to fit a logistic regression model. Stratification potential regarding outcome was internally validated using bootstrap, receiver-operator-characteristic (ROC)-analysis, Kaplan-Meier- and Cox-method, and compared to GTV, ADCmean and clinical factors. RESULTS: The best model was defined by 800<ADC<1100·10-6mm2/s and correlated significantly to treatment outcome (p = 0.003). Optimal HRS cut-off value was found to be 5.8 cm3 according to ROC-analysis. This HRS demonstrated highly significant stratification potential (p < 0.001, bootstrap AUC ≥ 0.84) similar to GTV size (p < 0.001, AUC ≥ 0.79), in contrast to ADCmean (p = 0.361, AUC = 0.53). CONCLUSIONS: A preclinical prognostic model defined by an ADC-based HRS was successfully retrained and validated in HNC patients treated with radiochemotherapy. After thorough external validation, such functional HRS based on a band of ADC values may in the future allow interventional response-adaptive MRI-guided radiotherapy in online and offline approaches.
引用
- Winter RM, Boeke S, Leibfarth S, et al. Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer. Radiother Oncol. 2024. PMID: 39733969. doi:10.1016/j.radonc.2024.110702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。